Sisomicin (Synonyms: Antibiotic 6640, SCH 13475) |
Catalog No.GC44894
One-Click Copy Product Info
|
Sisomicin is a naturally occurring aminoglycoside antibiotic produced by Micromonospora inyoensis and has strong activity against Gram-positive bacteria.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 32385-11-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Sisomicin is a naturally occurring aminoglycoside antibiotic produced by Micromonospora inyoensis and has strong activity against Gram-positive bacteria[1].
In vitro, Compared to the wild-type Mycobacterium smegmatis, the PdtaS gene deletion (ΔpdtaS) mutant shows increased sensitivity to sisomicin (2.3μg/ml; 3, 6, 9 and 24h)[2]. Sisomicin (20μg/mL; 30min) does not interfere with the function of polymorphonuclear neutrophils (PMN)[3].
In vivo, Hypertonic Sisomicin (20mg/ml) can be used for intracochlear perfusion to construct an inner ear injury model in mice[4]. Sisomicin (20mg/kg; i.p.) caused a decrease in neuromuscular twitch tension in rabbits[5].
References:
[1] Noone P. Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use. Drugs. 1984 Jun;27(6):548-78.
[2] Dadura K, Płocińska R, Rumijowska-Galewicz A, et al. PdtaS Deficiency Affects Resistance of Mycobacteria to Ribosome Targeting Antibiotics. Front Microbiol. 2017 Nov 3;8:2145.
[3] Le Moli S, Seminara R, D'Amelio R, et al. In vitro and in vivo effect of sisomicin and gentamycin on polymorphonuclear chemotaxis and phagocytosis. Int J Immunopharmacol. 1983;5(1):49-54.
[4] Maraslioglu-Sperber A, Blanc F, Heller S, et al. Hyperosmotic sisomicin infusion: a mouse model for hearing loss. Sci Rep. 2024 Jul 10;14(1):15903.
[5] Matsukawa S, Suh JH, Hashimoto Y, et al. Neuromuscular blocking actions of the aminoglycoside antibiotics sisomicin and micronomicin in the rabbit. Tohoku J Exp Med. 1997 Apr;181(4):471-3.
| Cell experiment [1]: | |
Cell lines | Mycobacterium smegmatis |
Preparation Method | The survival of M. smegmatis ΔpdtaS mutant cells grown in liquid medium with the addition of selected antibiotics was studied using standard colony-forming unit (CFU) methodology. Actively growing cells from the logarithmic stage of growth were diluted in 7H9 medium supplemented with OADC and Tween-80 to an OD600 of 0.1. Sisomicin at a final concentration of 2.3μg/ml was used. The kinetics of growth was measured by recording OD600 at 3, 6, 9 and 24h after the addition of antibiotics. At the 9 and 24h time points, 10-fold serial dilutions of cells were spread on 7H10 agar containing OADC. Plates were incubated at 37°C for 3-5 days, colonies were counted, and data were plotted using Excel. A Student's t-test was performed to determine the statistical significance between the test and control values. |
Reaction Conditions | 2.3μg/ml; 3, 6, 9 and 24h |
Applications | Compared to the wild-type Mycobacterium smegmatis, the PdtaS gene deletion (ΔpdtaS) mutant shows increased sensitivity to sisomicin. |
| Animal experiment [2]: | |
Animal models | Rabbits |
Preparation Method | Twenty rabbits weighing 2.2-4.4kg were subjected to tracheotomy after anesthesia induction. Mechanical ventilation was controlled to maintain arterial carbon dioxide pressure (PaCO₂) between 35-45mmHg. Blood pressure and arterial blood gas analysis were monitored through a catheterized carotid artery. The external jugular vein was cannulated for fluid (5%D/W, at a rate of 10ml/kg/hr) and drug administration. The left gastrocnemius tendon was cut and secured to a U-type force-displacement transducer. A heating pad was used to maintain body temperature above 36°C, and the muscle was housed in a clear enclosure warmed by a heat lamp. A thermometer in contact with the muscle surface measured muscle temperature. The left tibial nerve was cut after dissection from the sciatic nerve and covered with mineral oil. The cut tibial nerve was directly stimulated using a stimulator and 27 gauge thin-walled steel-needle electrodes. Maximal square-wave pulses (0.1ms duration) were delivered at a rate of 0.1Hz. The resultant isometric force of muscle twitch tension and arterial blood pressure were continuously recorded on a Nihon Kohden polygraph. When a stable twitch was obtained, an initial dose of Sisomicin (20mg/kg, n=7) was administered intravenously, and the initial dose and maximum percentage of twitch inhibition were determined. Additional Sisomicin (10mg/kg) was given to study the response to twitch inhibition exceeding 90%. |
Dosage form | 20mg/kg; i.p. |
Applications | Sisomicin caused a decrease in neuromuscular twitch tension in rabbits. |
References: | |
| Cas No. | 32385-11-8 | SDF | |
| Synonyms | Antibiotic 6640, SCH 13475 | ||
| Canonical SMILES | N[C@H]1[C@](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)([H])OC(CN)=CC1 | ||
| Formula | C19H37N5O7 | M.Wt | 447.5 |
| Solubility | DMF: 25 mg/ml,DMSO: 30 mg/ml,Ethanol: 25 mg/ml,PBS (pH 7.2): 5 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2346 mL | 11.1732 mL | 22.3464 mL |
| 5 mM | 446.9 μL | 2.2346 mL | 4.4693 mL |
| 10 mM | 223.5 μL | 1.1173 mL | 2.2346 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)